- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Global Immunoassay Market to Reach $47.7 Billion by 2030
Driven by rising chronic disease prevalence and demand for advanced diagnostics
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
According to a new report by MarketsandMarkets, the global immunoassay market is projected to reach $47.7 billion by 2030, growing at a CAGR of 6.1% from 2025. The market is driven by the expanding elderly population, increasing incidence of chronic diseases, and growing demand for early, accurate diagnostic tools. Key players in the space include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific.
Why it matters
Immunoassays are essential diagnostic tools for detecting and monitoring a wide range of health conditions, from infectious diseases to cancer and endocrine disorders. As the global population ages and chronic disease rates rise, the demand for reliable, sensitive immunoassay-based tests will continue to grow, driving significant market expansion.
The details
The immunoassay market is segmented by product (reagents & kits, analyzers), technology (ELISA, CLIA, Western blot), specimen (blood, saliva, urine), application (infectious diseases, endocrinology), and end-user (hospitals & clinics, laboratories). Reagents and kits currently dominate the market due to their recurring use in diagnostic workflows. ELISA is the leading technology segment thanks to its versatility in infectious disease and cancer screening. Hospitals and clinics are the largest end-users, performing the majority of immunoassay-based tests.
- The immunoassay market is projected to reach $47.7 billion by 2030.
- From 2025 to 2030, the market is expected to grow at a CAGR of 6.1%.
The players
Abbott
A leading global healthcare company that develops immunoassay-based diagnostic tests.
F. Hoffmann-La Roche Ltd.
A Swiss multinational healthcare company and a major player in the immunoassay market.
Siemens Healthineers AG
A German medical technology company that provides a range of immunoassay analyzers and reagents.
Thermo Fisher Scientific Inc.
A US-based biotechnology company that develops and manufactures immunoassay products and instruments.
Danaher
A US-based conglomerate with a strong presence in the in vitro diagnostics and immunoassay market.
What’s next
As the immunoassay market continues to grow, key players are expected to focus on mergers, acquisitions, investments, and new product developments to strengthen their market positions and expand their product portfolios.
The takeaway
The rising demand for early, accurate, and efficient diagnostic tools driven by the aging population and the increasing prevalence of chronic diseases is fueling the growth of the global immunoassay market. This trend highlights the essential role of immunoassays in modern healthcare and the potential for continued innovation and investment in this critical diagnostic segment.
